Socioeconomic Factors Impact Likelihood of Early Stage Pancreatic Cancer Surgery

Share this content:
A newly published study has found that African American, Hispanic, single, and uninsured patients were significantly less likely to have tumors removed.
A newly published study has found that African American, Hispanic, single, and uninsured patients were significantly less likely to have tumors removed.

Despite the strong association between surgical resection of early-stage pancreatic cancer and improved survival, a newly published study has found that African American, Hispanic, single, and uninsured patients were significantly less likely to have their tumors removed.1

The study, conducted by Jason S. Gold, MD, of Harvard Medical School and the VA Boston Healthcare System and colleagues, looked at whether socioeconomic variables including race, ethnicity, marital status, insurance status, and geographic location were associated with disparities in the utilization of surgical resection as a treatment for early-stage pancreatic cancer. It also examined whether those variables were independently associated with disease-specific survival in patients who did undergo resection.

The retrospective cohort analysis of 17 530 patients with localized, nonmetastatic pancreatic cancer diagnosed between January 1, 2004, and December 31, 2011, found an increased likelihood of resection in patients who were male (odds ratio [OR] = 1.20; 95% CI, 1.13 - 1.27); younger (OR = 0.95; 95% CI, 0.94 - 0.95); white (OR = 1.16; 95% CI, 1.08 - 1.26) or non-African American (for African American, OR = 0.80; 95% CI, 0.73 - 0.88); non-Hispanic (for Hispanic, OR = 0.83; 95% CI, 0.74 - 0.93); married (OR = 1.78; 95% CI, 1.67 -  1.89); or located in the Northeast (OR = 1.62; 95% CI, 1.50 - 1.76; all P < .001).

“Our research further confirmed that, as expected, resection is associated with improved survival,” the study's authors wrote.

RELATED: Cutoff for Malignancy for Pancreatic Neuroendocrine Tumors Could Be Decreased

Specifically, they found that the median disease-specific survival of patients who underwent resection was 21 months (95% CI, 20.3 -21.7); the median disease-specific survival of patients who did not was 6 months (95% CI, 5.8 - 6.2).

“Sex, race, ethnicity, marital status, and insurance status were not independently associated with disease-specific survival after resection,” they noted.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters